Merck to acquire Cidara, maker of a flu prevention drug, for $9.2B
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Merck said Friday it would buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal, as the pharma giants widens its pipeline to counter the impending revenue hit as its mega-blockbuster…